House introduces bipartisan bill on AI in banking and housing
The bill would require a report on how these industries use AI to valuate homes and underwrite loans
Read more...Heart disease is the leading cause of death in the United States with one person dying from it every 34 seconds; one form of heart disease is called cardiac amyloidosis, a.k.a. stiff heart syndrome, which occurs when amyloid deposits take the place of normal heart muscle. This disease, while rare, has been associated with a 5-year mortality of 44% to 65% after diagnosis.
That's why Anumana, an AI-driven company that develops ECG algorithms enabling early disease diagnosis and intervention, announced a multi-year agreement with Pfizer earlier this week. The plan is to develop a new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosis.
Founded in 2021 in collaboration with the Mayo Clinic Platform, Anumana's software devices are designed for real-world physician use, integrating into existing workflows at the point of care to reduce costs and enhance quality of life.
The company has licensed Mayo Clinic AI-ECG algorithms for low ejection fraction, pulmonary hypertension, and hyperkalemia, all of which have received Breakthrough Device Designation from the FDA. These algorithms have been validated by over 75 peer-reviewed publications.
This new agreement with Pfizer will help Anumana in its efforts to implement AI-enabled early detection software that can reveal signals from ECGs, which humans cannot interpret. The company believes that since ECG's are ubiquitous and non-invasive, it gives AI-ECG algorithms the potential to reach a larger number of patients earlier.
“The challenge in diagnosing cardiac amyloidosis can prevent patients from getting treatment while the disease continues to progress,” David McMullin, chief business officer of Anumana, said in a statement.
“We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.”
The Boston-based Anumana has raised over $117 million in venture funding from investors that include MedTech Innovator, Mayo Clinic Ventures, NTT Venture Capital, Matrix Partners, and Nference. The company also recently acquired NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology.
(Image source: epa.gov)
The bill would require a report on how these industries use AI to valuate homes and underwrite loans
Read more...The artists wrote an open letter accusing OpenAI of misleading and using them
Read more...The role will not be filled by Elon Musk, though he will be involved in who is chosen
Read more...